Noriko Koizumi

This inventor holds 23 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Corneal Endothelial Therapy. Top assignees: The Doshisha, Senju Pharmaceutical Co., Ltd., Kyoto Prefectural Public University Corporation. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Noriko Koizumi. Retrieved from https://idiyas.com/inventor/noriko-koizumi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 6)

% Patents Active = 82.6

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)

Location History:

Kyoto, JP (2014 - 2023)
Kyotanabe, JP (2017 - 2024)

Company Filing History:

Senju Pharmaceutical Co., Ltd.

patents

9 out of 60

Kyoto Prefectural Public University Corporation

Jcr Pharmaceuticals Co., Ltd.

patents

7. 5 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Corneal Endothelium

Cell Adhesion

mTOR Inhibitor

Laminin

TGF-β Signaling

Cell Proliferation

Therapeutic Drug

Caspase Inhibitor

Cell Culture

Endoplasmic Reticulum

Cell Therapy

Differentiation Marker

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12702672 - Agent for promoting corneal endothelial cell adhesion (2026-08-11),

2. 12343356 - mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof (2025-07-01),

3. 11857544 - Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases (2024-01-02),

4. 11839618 - Agent for promoting corneal endothelial cell adhesion (2023-12-12),

5. 11730722 - Corneal endothelium ECM therapeutic medicaments (2023-08-22),

6. 11633477 - Treatment of cornea using laminin (2023-04-25),

7. 11633404 - Agent for promoting corneal endothelial cell adhesion (2023-04-25),

8. 11624053 - Application of laminin to corneal endothelial cell culture (2023-04-11),

9. 11576914 - Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof (2023-02-14),

10. 11446263 - Caspase inhibitor-containing drug for treating or preventing disorders caused by TGF-β, and applications thereof (2022-09-20),

11. 11445723 - Method and container for preserving corneal endothelial cells (2022-09-20),

12. 11433090 - mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof (2022-09-06),

13. 11382904 - Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium (2022-07-12),

14. 10980787 - Drug for treating or preventing disorder caused by TGF-B signals, and application thereof (2021-04-20),

15. 10959997 - Combined agent for cell therapy of corneal endothelial cell (2021-03-30),

Title: Noriko Koizumi: Pioneering Innovations in Corneal Endothelial Treatment

Introduction

Noriko Koizumi is a prominent inventor based in Kyoto, Japan, known for his significant contributions to the field of ocular health. With a remarkable total of 21 patents to his name, Koizumi has dedicated his career to developing advanced treatments for corneal endothelial diseases, which affect the inner layer of the cornea.

Latest Patents

Koizumi's most recent patents focus on innovative compositions and methods for addressing corneal issues. One of his notable inventions is a composition for treating or preventing corneal endothelial diseases, specifically utilizing (T)EW-7197, a compound designed to alleviate symptoms and disorders of the corneal endothelium. Another important patent includes an agent promoting corneal endothelial cell adhesion, which features a Rho kinase inhibitor and serves multiple purposes, such as providing a culture medium and preservation solutions for corneal cells.

Career Highlights

Throughout his career, Noriko Koizumi has worked with esteemed organizations, including Doshisha University and Senju Pharmaceutical Co., Ltd. His research and innovative endeavors have greatly advanced the understanding and treatment of corneal conditions, making him a key player in the field of ophthalmology.

Collaborations

Koizumi has collaborated with notable colleagues, including Naoki Okumura and Shigeru Kinoshita. These collaborations have further enriched his work, fostering an environment of innovation and progressive research in eye health.

Conclusion

Noriko Koizumi stands out as a visionary inventor whose contributions are paving the way for better treatments of corneal endothelial diseases. With his ongoing research and numerous patents, he continues to shape the future of ocular health through innovative solutions.

Profile summary based on public USPTO records.